Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literature

Vaccine

Volumn 35, Issue 22, 2017, Pages 2882-2891

  Tsaban, Gal ^a,b   Ben Shimol, Shalom ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Herd protection; Indirect immunity; Invasive pneumococcal disease (IPD); Pneumococcal conjugated vaccine (PCV); Pneumonia

Indexed keywords

PNEUMOCOCCUS VACCINE; VACCINE;

CANADA; GROUPS BY AGE; HOSPITAL ADMISSION; HUMAN; MEDLINE; PNEUMOCOCCAL INFECTION; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNITED KINGDOM; VACCINATION; ADOLESCENT; ADULT; AGE; AGED; CHILD; FEMALE; HERD IMMUNITY; IMMUNOLOGY; MALE; MICROBIOLOGY; MIDDLE AGED; PRESCHOOL CHILD; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CANADA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNITY, HERD; IMMUNIZATION PROGRAMS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 85018863031     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.04.032     Document Type: Review

References (67)

1. [1] O'Brien, K.L., Wolfson, L.J., Watt, J.P., Henkle, E., Deloria-Knoll, M., McCall, N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374 (2009), 893–902.
2. [2] Fedson, D.S., Anthony, J., Scott, G., The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 17 (1999), S11–S18.
3. [3] Drijkoningen, J., Rohde, G., Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 20 (2014), 45–51.
4. [4] Fitzwater, S.P., Chandran, A., Santosham, M., Johnson, H.L., The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 31 (2012), 501–508.
5. [5] Bosch, A.A., van Houten, M.A., Bruin, J.P., Wijmenga-Monsuur, A.J., Trzciński, K., Bogaert, D., et al. Nasopharyngeal carriage of Streptococcus pneumoniae and other bacteria in the 7th year after implementation of the pneumococcal conjugate vaccine in the Netherlands. Vaccine 34 (2016), 531–539.
6. [6] Hammitt, L.L., Bruden, D.L., Butler, J.C., Baggett, H.C., Hurlburt, D.A., Reasonover, A., et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Diseases 193 (2006), 1487–1494.
7. [7] Weil-Olivier, C., van der Linden, M., de Schutter, I., Dagan, R., Mantovani, L., Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis, 12, 2012, 1.
8. [8] Schiffner-Rohe, J., Witt, A., Hemmerling, J., von Eiff, C., Leverkus, F.-W., Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk – a systematic review and meta-analysis. PLoS ONE, 11, 2016, e0146338.
9. [9] Kraicer-Melamed, H., O'Donnell, S., Quach, C., The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis. Vaccine 34 (2016), 1540–1550.
10. [10] Andrews, N.J., Waight, P.A., George, R.C., Slack, M.P., Miller, E., Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 30 (2012), 6802–6808.
11. [11] Ardanuy, C., Tubau, F., Pallares, R., Calatayud, L., Domínguez, M.A., Rolo, D., et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997–2007. Clin Infect Dis 48 (2009), 57–64.
12. [12] Black, S., Shinefield, H., Baxter, R., Austrian, R., Elvin, L., Hansen, J., et al. Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine 24 (2006), S79–S80.
13. [13] Centers for Disease Control and Prevention (CDC)(Reingold). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease–United States, 1998-2003. Morbidity and Mortality Weekly Report (MMWR) 2005;54:893.
14. [14] Demczuk, W.H., Martin, I., Griffith, A., Lefebvre, B., McGeer, A., Lovgren, M., et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012. Can J Microbiol 59 (2013), 778–788.
15. [15] Elberse, K.E., van der Heide, H.G., Witteveen, S., van de Pol, I., Schot, C.S., van der Ende, A., et al. Changes in the composition of the pneumococcal population and in IPD incidence in The Netherlands after the implementation of the 7-valent pneumococcal conjugate vaccine. Vaccine 30 (2012), 7644–7651.
16. [16] Hanna, J.N., Humphreys, J.L., Murphy, D.M., Invasive pneumococcal disease in Indigenous people in north Queensland: an update, 2005–2007. Med J Australia, 189, 2008, 43.
17. [17] Kellner, J.D., Vanderkooi, O.G., MacDonald, J., Church, D.L., Tyrrell, G.J., Scheifele, D.W., Changing epidemiology of invasive pneumococcal disease in Canada, 1998–2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 49 (2009), 205–212.
18. [18] Meichtry, J., Born, R., Küffer, M., Zwahlen, M., Albrich, W.C., Brugger, S.D., et al. Serotype epidemiology of invasive pneumococcal disease in Swiss adults: a nationwide population-based study. Vaccine 32 (2014), 5185–5191.
19. [19] Metlay, J.P., Fishman, N.O., Joffe, M., Edelstein, P.H., Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine 24 (2006), 468–475.
20. [20] Miller, E., Andrews, N.J., Waight, P.A., Slack, M.P., George, R.C., Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 11 (2011), 760–768.
21. [21] Regev-Yochay, G., Paran, Y., Bishara, J., Oren, I., Chowers, M., Tziba, Y., et al. Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study. Vaccine 33 (2015), 1135–1142.
22. [22] Rodrigo, C., Bewick, T., Sheppard, C., Greenwood, S., Mckeever, T.M., Trotter, C.L., et al. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J 45 (2015), 1632–1641.
23. [23] Rudnick, W., Liu, Z., Shigayeva, A., Low, D.E., Green, K., Plevneshi, A., et al. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995–2011. Vaccine 31 (2013), 5863–5871.
24. [24] Sahni, V., Naus, M., Hoang, L., Tyrrell, G.J., Martin, I., Patrick, D.M., The epidemiology of invasive pneumococcal disease in British Columbia following implementation of an infant immunization program: increases in herd immunity and replacement disease. Can J Public Health, 2012, 29–33.
25. [25] Shafinoori, S., Ginocchio, C.C., Greenberg, A.J., Yeoman, E., Cheddie, M., Rubin, L.G., Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults. Pediatr Infect Dis J 24 (2005), 10–16.
26. [26] Simonsen, L., Taylor, R.J., Young-Xu, Y., Haber, M., May, L., Klugman, K.P., Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio, 2, 2011, e00309-10.
27. [27] Simonsen, L., Taylor, R.J., Schuck-Paim, C., Lustig, R., Haber, M., Klugman, K.P., Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Resp Med 2 (2014), 387–394.
28. [28] Tsigrelis, C., Tleyjeh, I.M., Lahr, B.D., Nyre, L.M., Virk, A., Baddour, L.M., Trends in invasive pneumococcal disease among older adults in Olmsted County, Minnesota. J Infect 59 (2009), 188–193.
29. [29] Waight, P.A., Andrews, N.J., Ladhani, S.N., Sheppard, C.L., Slack, M.P., Miller, E., Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Resp Med 15 (2015), 535–543.
30. [30] Hanna, J.N., Humphreys, J.L., Murphy, D.M., Smith, H.V., Invasive pneumococcal disease in non-Indigenous people in north Queensland, 2001–2009. Med J Australia, 193, 2010, 392.
31. [31] Harboe, Z.B., Dalby, T., Weinberger, D.M., Benfield, T., Mølbak, K., Slotved, H.C., et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 59 (2014), 1066–1073.
32. [32] Hennessy, T.W., Singleton, R.J., Bulkow, L.R., Bruden, D.L., Hurlburt, D.A., Parks, D., et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity. Vaccine 23 (2005), 5464–5473.
33. [33] Ingels, H., Rasmussen, J., Andersen, P.H., Harboe, Z.B., Glismann, S., Konradsen, H., et al. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Vaccine 30 (2012), 3944–3950.
34. [34] Lexau, C.A., Lynfield, R., Danila, R., Pilishvili, T., Facklam, R., Farley, M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294 (2005), 2043–2051.
35. [35] Johnson, D.R., D'Onise, K., Holland, R.A., Raupach, J.C., Koehler, A.P., Pneumococcal disease in South Australia: vaccine success but no time for complacency. Vaccine 30 (2012), 2206–2211.
36. [36] Gabarrot, G.G., Vega, M.L., Giffoni, G.P., Hernández, S., Cardinal, P., Félix, V., et al. Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country. PLoS ONE, 9, 2014, e112337.
37. [37] Muhammad, R.D., Oza-Frank, R., Zell, E., Link-Gelles, R., Narayan, K.V., Schaffner, W., et al. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis 56 (2013), e59–e67.
38. [38] Patrzalek, M., Gorynski, P., Albrecht, P., Indirect population impact of universal PCV7 vaccination of children in a 2+ 1 schedule on the incidence of pneumonia morbidity in Kielce, Poland. Eur J Clin Microbiol Infect Dis 31 (2012), 3023–3028.
39. [39] Steens, A., Bergsaker, M.A.R., Aaberge, I.S., Rønning, K., Vestrheim, D.F., Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 31 (2013), 6232–6238.
40. [40] Vestrheim, D.F., Høiby, E.A., Bergsaker, M.R., Rønning, K., Aaberge, I.S., Caugant, D.A., Indirect effect of conjugate pneumococcal vaccination in a 2+ 1 dose schedule. Vaccine 28 (2010), 2214–2221.
41. [41] Vila-Corcoles, A., Ochoa-Gondar, O., Guzman-Avalos, A., Gomez-Bertomeu, F., Figuerola-Massana, E., Raga-Luria, X., et al. Incidence of pneumococcal infections among children under 15 years in southern Catalonia throughout the heptavalent conjugate vaccine era, 2002–2009. Infection 41 (2013), 439–446.
42. [42] von Gottberg, A., de Gouveia, L., Tempia, S., Quan, V., Meiring, S., von Mollendorf, C., et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med 371 (2014), 1889–1899.
43. [43] Albrich, W., Baughman, W., Schmotzer, B., Farley, M., Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 44 (2007), 1569–1576.
44. [44] Becker-Dreps, S., Amaya, E., Liu, L., Rocha, J., Briceño, R., Moreno, G., et al. Impact of a combined pediatric and adult pneumococcal immunization program on adult pneumonia incidence and mortality in Nicaragua. Vaccine 33 (2015), 222–227.
45. [45] Elston, J., Santaniello-Newton, A., Meigh, J., Harmer, D., Allgar, V., Allison, T., et al. Increasing incidence of invasive pneumococcal disease and pneumonia despite improved vaccination uptake: surveillance in Hull and East Yorkshire, UK, 2002–2009. Epidemiol Infect 140 (2012), 1252–1266.
46. [46] Griffin, M.R., Zhu, Y., Moore, M.R., Whitney, C.G., Grijalva, C.G., US hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 369 (2013), 155–163.
47. [47] Grijalva, C.G., Nuorti, J.P., Arbogast, P.G., Martin, S.W., Edwards, K.M., Griffin, M.R., Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369 (2007), 1179–1186.
48. [48] Jardine, A., Menzies, R.I., McIntyre, P.B., Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J 29 (2010), 607–612.
49. [49] Lai, C.-C., Lin, S.-H., Liao, C.-H., Sheng, W.-H., Hsueh, P.-R., Decline in the incidence of invasive pneumococcal disease at a medical center in Taiwan, 2000–2012. BMC Infect Dis, 14, 2014, 1.
50. [50] Le Meur, J.-B., Lefebvre, B., Proulx, J.-F., Déry, S., Pépin, J., De Wals, P., Impact of pneumococcal vaccines use on invasive pneumococcal disease in Nunavik (Quebec) from 1997 to 2010. Int J Circumpolar Health, 2014, 1997, 73.
51. [51] Lin, S.H., Tan, C.K., Lai, C.C., Wang, C.Y., Hsueh, P.R., Declining incidence of nonbacteremic pneumococcal pneumonia in hospitalized elderly patients at a tertiary care hospital after the introduction of pneumococcal vaccines in Taiwan, 2004 to 2008. J Am Geriatr Soc 58 (2010), 195–196.
52. [52] Nelson, J.C., Jackson, M., Yu, O., Whitney, C.G., Bounds, L., Bittner, R., et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine 26 (2008), 4947–4954.
53. [53] Pilishvili, T., Lexau, C., Farley, M.M., Hadler, J., Harrison, L.H., Bennett, N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201 (2010), 32–41.
54. [54] Tsai, C.J., Griffin, M.R., Nuorti, J.P., Grijalva, C.G., Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin Infect Dis 46 (2008), 1664–1672.
55. [55] Vila-Corcoles, A., Ochoa-Gondar, O., Gomez-Bertomeu, F., Raga-Luria, X., Group ES. Invasive pneumococcal disease in Catalonian elderly people, 2002–2009: serotype coverage for different anti-pneumococcal vaccine formulations at the beginning of the new conjugate vaccines era. Vaccine 29 (2011), 7430–7434.
56. [56] Grau, I., Ardanuy, C., Cubero, M., Benitez, M.A., Liñares, J., Pallares, R., Declining mortality from adult pneumococcal infections linked to children's vaccination. J Infect 72 (2016), 439–449.
57. [57] De Wals, P., Lefebvre, B., Markowski, F., Deceuninck, G., Defay, F., Douville-Fradet, M., et al. Impact of 2+ 1 pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine 32 (2014), 1501–1506.
58. [58] Bruce, M.G., Singleton, R., Bulkow, L., Rudolph, K., Zulz, T., Gounder, P., et al. Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska. Vaccine 33 (2015), 4813–4819.
59. [59] Butler, J.C., Schuchat, A., Epidemiology of pneumococcal infections in the elderly. Drugs Aging 15 (1999), 11–19.
60. [60] Clutterbuck, E.A., Lazarus, R., Yu, L.-M., Bowman, J., Bateman, E.A., Diggle, L., et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 205 (2012), 1408–1416.
61. [61] Fedson D, Musher D. Pneumococcal polysaccharide vaccine, Ch. 22. Vaccines. Plotkin SA, editor. Orenstein WA 2004:529–88.
62. [62] Fedson, D.S., Guppy, M.J., Pneumococcal vaccination of older adults: conjugate or polysaccharide?. Human Vaccines Immunother 9 (2013), 1382–1384.
63. [63] Sisk, J.E., Moskowitz, A.J., Whang, W., Lin, J.D., Fedson, D.S., McBean, A.M., et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 278 (1997), 1333–1339.
64. [64] Jackson, L.A., Gurtman, A., van Cleeff, M., Jansen, K.U., Jayawardene, D., Devlin, C., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 31 (2013), 3577–3584.
65. [65] Jackson, L.A., Gurtman, A., Rice, K., Pauksens, K., Greenberg, R.N., Jones, T.R., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 31 (2013), 3585–3593.
66. [66] Lazarus, R., Clutterbuck, E., Yu, L.-M., Bowman, J., Bateman, E.A., Diggle, L., et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 52 (2011), 736–742.
67. [67] Bonten, M.J., Huijts, S.M., Bolkenbaas, M., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 372:12 (2015 Mar 19), 1114–1125.